Maintaining nocturnal glycemic status using insulin glargine
Abstract
Hypoglycemia is a major limiting factor in achieving glycemic control in patients with diabetes. The American Diabetes Association recommends an HgA1C goal of less than 7% in most patients, and the American Association of Clinical Endocrinologists recommends an HgA1C less than 6.5%, if achievable without significant hypoglycemia. Landmark studies, such as the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Trial have clearly shown that tight glycemic control can prevent or delay the development of microvascular complications, such as retinopathy, nephropathy, and neuropathy, in type 1 and type 2 diabetes, but with aggressive glycemic targets comes an increase of hypoglycemia risk.
Downloads
References
Ortiz MR. Hypoglycemia in Diabetes. Nurs Clin North Am. 2017;52(4):565- 574. doi:10.1016/j.cnur.2017.07.006
McCall AL. Insulin therapy and hypoglycemia. Endocrinol Metab Clin North Am. 2012;41(1):57-87. doi:10.1016/j.ecl.2012.03.001
The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
Yale JF. Nocturnal hypoglycemia in patients with insulin-treated diabetes. Diabetes Res Clin Pract. 2004;65(SUPPL.). doi:10.1016/j.diabres.2004.07.007
Enedetti MAMA. Reduced Hypoglycemia Risk With Insulin Glargine. Diabetes Care. 2005;(September 2004).
Nagel N, Graewert MA, Gao M, et al. The quaternary structure of insulin glargine and glulisine under formulation conditions. Biophys Chem. 2019;253(July):106226. doi:10.1016/j.bpc.2019.106226
Mullins P, Sharplin P Y-JH, Riddle MC HH. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in Type 1 and Type 2 diabetes mellitus. Clin Ther. 2007;29(8):1607–1619.
Betônico CC, Titan SMO, Lira A, et al. Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4. Clin Ther. 2019;41(10):2008-2020.e3. doi:10.1016/j.clinthera.2019.07.011
